As of Aug 16
| +0.74 / +0.64%|
The 22 analysts offering 12-month price forecasts for Edwards Lifesciences Corp have a median target of 132.00, with a high estimate of 155.00 and a low estimate of 94.00. The median estimate represents a +14.22% increase from the last price of 115.57.
The current consensus among 25 polled investment analysts is to Buy stock in Edwards Lifesciences Corp. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.